Regarding the mechanisms of extended-spectrum β-lactamase (ESBL) production in gram-negative bacteria, all of the following are true EXCEPT:

Explanation

## Mechanism of ESBL Resistance **Key Point:** Extended-spectrum β-lactamases (ESBLs) are enzymes that confer resistance to third- and fourth-generation cephalosporins and aztreonam by hydrolyzing the β-lactam ring. Understanding their characteristics is critical for infection control and antimicrobial stewardship. ### ESBL Classification and Origin | ESBL Type | Origin | Prevalence | Key Features | |-----------|--------|-----------|---------------| | TEM | Chromosomal mutation in TEM-1 (Gram-negative) | Historically common | Inhibited by clavulanic acid | | SHV | Chromosomal mutation in SHV-1 (Klebsiella) | Moderate | Inhibited by clavulanic acid | | CTX-M | Chromosomal origin (Kluyvera spp.) | **Most prevalent globally** | Inhibited by clavulanic acid | **High-Yield:** CTX-M ESBLs are now the dominant ESBL type worldwide, particularly in community-acquired infections. They show superior hydrolysis of cefotaxime and ceftriaxone compared to TEM and SHV. ### Genetic and Phenotypic Properties 1. **Plasmid-mediated transmission:** ESBLs are typically encoded on plasmids (often conjugative), allowing horizontal gene transfer between species and even genera [cite:Prescott's Microbiology Ch 35] 2. **Clavulanic acid inhibition:** All three major ESBL types (TEM, SHV, CTX-M) are inhibited by β-lactamase inhibitors like clavulanic acid, ampicillin-sulbactam, and piperacillin-tazobactam 3. **Point mutations:** SHV and TEM ESBLs arise from point mutations in the active site of their chromosomal precursors, altering substrate specificity ### Why Option 3 Is Incorrect **Clinical Pearl:** ESBL-producing organisms are **resistant** to third-generation cephalosporins (ceftriaxone, cefotaxime, ceftazidime) by definition. The CLSI and EUCAST breakpoints classify ESBL producers as **resistant** to these agents, even if the MIC appears low in vitro. This is because: - ESBL production can be heterogeneous and variable under different growth conditions - Inoculum effects may lead to treatment failure despite in vitro susceptibility - Clinical failures have been documented with third-generation cephalosporins in ESBL infections **Warning:** Do NOT rely on in vitro susceptibility testing alone for ESBL producers. Phenotypic confirmation (e.g., ESBL inhibitor disk test) and use of carbapenems or fluoroquinolones is recommended. ### Correct Statements (Options 1, 2, 4) - **Option 1:** CTX-M ESBLs are indeed inhibited by clavulanic acid and are the most prevalent ESBLs globally ✓ - **Option 2:** SHV and TEM originated from chromosomal β-lactamases through point mutations ✓ - **Option 4:** ESBLs are plasmid-encoded and transferable horizontally ✓ ### Management Implications ```mermaid flowchart TD A[Gram-negative isolate with resistance to 3rd gen cephalosporin]:::outcome --> B{ESBL suspected?}:::decision B -->|Yes: Confirm with inhibitor disk test| C[ESBL confirmed]:::outcome C --> D[Avoid 3rd gen cephalosporins]:::urgent D --> E[Use carbapenem or fluoroquinolone]:::action B -->|No: Consider other mechanisms| F[Ampicillinase, AmpC, Carbapenemase]:::outcome ```